BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005;65 Suppl 2:29-39. [PMID: 16398060 DOI: 10.2165/00003495-200565002-00005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Tomohiro T, Kumai T, Sato T, Takeba Y, Kobayashi S, Kimura K. Hypertension aggravates glomerular dysfunction with oxidative stress in a rat model of diabetic nephropathy. Life Sciences 2007;80:1364-72. [DOI: 10.1016/j.lfs.2006.11.054] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
2 Wang Y, Hu Y, Li Y, Li H, Chu S, Zhu D, Gao P. Association of renal function with the ambulatory arterial stiffness index and pulse pressure in hypertensive patients. Hypertens Res 2012;35:201-6. [DOI: 10.1038/hr.2011.167] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
3 Huang RS, Cheng YM, Zeng XX, Kim S, Fu P. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease. Chin Med J (Engl) 2016;129:562-9. [PMID: 26904991 DOI: 10.4103/0366-6999.176987] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
4 Mir O, Coriat R, Ropert S, Cabanes L, Blanchet B, Camps S, Billemont B, Knebelmann B, Goldwasser F. Treatment of bevacizumab-induced hypertension by amlodipine. Invest New Drugs 2012;30:702-7. [PMID: 20878444 DOI: 10.1007/s10637-010-9549-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
5 Zhao Y, Zhao S, Kuge Y, Tamaki N. Elevated 18F-FDG levels in blood and organs after angiotensin II receptor blocker administration: experiment in mice administered telmisartan. J Nucl Med 2013;54:1384-8. [PMID: 23833272 DOI: 10.2967/jnumed.111.100248] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
6 El Hindi S, Reiser J. TRPC channel modulation in podocytes-inching toward novel treatments for glomerular disease. Pediatr Nephrol 2011;26:1057-64. [PMID: 21161284 DOI: 10.1007/s00467-010-1718-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lindeman RD. Hypertension and kidney protection in the elderly: what is the evidence in 2007? Int Urol Nephrol 2007;39:669-78. [PMID: 17487566 DOI: 10.1007/s11255-007-9207-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
8 Hu MC, Kuro-o M, Moe OW. Secreted klotho and chronic kidney disease. Adv Exp Med Biol 2012;728:126-57. [PMID: 22396167 DOI: 10.1007/978-1-4614-0887-1_9] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 8.8] [Reference Citation Analysis]
9 Geng TT, Talaei M, Jafar TH, Yuan JM, Koh WP. Pulse Pressure and the Risk of End-Stage Renal Disease Among Chinese Adults in Singapore: The Singapore Chinese Health Study. J Am Heart Assoc 2019;8:e013282. [PMID: 31766974 DOI: 10.1161/JAHA.119.013282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Pletz J, Enoch SJ, Jais DM, Mellor CL, Pawar G, Firman JW, Madden JC, Webb SD, Tagliati CA, Cronin MTD. A critical review of adverse effects to the kidney: mechanisms, data sources, and in silico tools to assist prediction. Expert Opin Drug Metab Toxicol 2018;14:1225-53. [PMID: 30345815 DOI: 10.1080/17425255.2018.1539076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
11 Mohanan A, Gupta R, Dubey A, Jagtap V, Mandhare A, Gupta RC, Chauthaiwale V, Dutt C. TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats. Int J Hypertens 2011;2011:751513. [PMID: 22235363 DOI: 10.4061/2011/751513] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
12 Ji H, Menini S, Zheng W, Pesce C, Wu X, Sandberg K. Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension in rats. Exp Physiol 2008;93:648-57. [PMID: 18296494 DOI: 10.1113/expphysiol.2007.041392] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 6.2] [Reference Citation Analysis]
13 Flaa A, Aksnes TA, Strand A, Kjeldsen SE. Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials. Expert Rev Cardiovasc Ther 2007;5:451-61. [PMID: 17489670 DOI: 10.1586/14779072.5.3.451] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
14 Vlcek M, Bur A, Woisetschläger C, Herkner H, Laggner AN, Hirschl MM. Association between hypertensive urgencies and subsequent cardiovascular events in patients with hypertension. J Hypertens 2008;26:657-62. [PMID: 18327073 DOI: 10.1097/HJH.0b013e3282f4e8b6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
15 Li Y, Shen M, Ferens D, Broughton BRS, Murthi P, Saini S, Widdop RE, Ricardo SD, Pinar AA, Samuel CS. Combining mesenchymal stem cells with serelaxin provides enhanced renoprotection against 1K/DOCA/salt-induced hypertension. Br J Pharmacol 2021;178:1164-81. [PMID: 33450051 DOI: 10.1111/bph.15361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Burnier M, Lin S, Ruilope L, Bader G, Durg S, Brunel P. Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis. Blood Press 2019;28:358-74. [PMID: 31392910 DOI: 10.1080/08037051.2019.1644155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 Bakris GL, Tarka EA, Waterhouse B, Goulding MR, Madan A, Anderson KM. Cardiovascular Risk Factors in Hypertension: Rationale and Design of Studies to Investigate the Effects of Controlled-Release Carvedilol on Regression of Left Ventricular Hypertrophy and Lipid Profile. The American Journal of Cardiology 2006;98:46-52. [DOI: 10.1016/j.amjcard.2006.08.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
18 Wenzel RR, Littke T, Kuranoff S, Jürgens C, Bruck H, Ritz E, Philipp T, Mitchell A; SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009;20:655-64. [PMID: 19144760 DOI: 10.1681/ASN.2008050482] [Cited by in Crossref: 163] [Cited by in F6Publishing: 63] [Article Influence: 13.6] [Reference Citation Analysis]
19 Hansen PB, Poulsen CB, Walter S, Marcussen N, Cribbs LL, Skøtt O, Jensen BL. Functional Importance of L- and P/Q-Type Voltage-Gated Calcium Channels in Human Renal Vasculature. Hypertension 2011;58:464-70. [DOI: 10.1161/hypertensionaha.111.170845] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
20 van Dokkum RP, Buikema H. Possible new druggable targets for the treatment of nephrosis. Perhaps we should find them in caveolea? Curr Opin Pharmacol 2009;9:132-8. [PMID: 19157981 DOI: 10.1016/j.coph.2008.12.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
21 Vettoretti S, Vavrinec P, Ochodnicky P, Deelman LE, De Zeeuw D, Henning RH, Buikema H. Renal endothelial function is associated with the anti-proteinuric effect of ACE inhibition in 5/6 nephrectomized rats. Am J Physiol Renal Physiol 2016;310:F1047-53. [PMID: 26911850 DOI: 10.1152/ajprenal.00325.2015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
22 Georgaki-Angelaki E, Stergiou N, Naoum E, Papassotiriou I, Anagnostakou M. Olmesartan medoxomil-induced acute renal failure in a premature newborn following maternal exposure during pregnancy: a case report and review of the literature. NDT Plus 2009;2:295-7. [PMID: 25984019 DOI: 10.1093/ndtplus/sfp045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Sharma R, Raghuram TC, Rao UB, Moffatt RJ, Krishnaswamy K. The effect of fat intake and antihypertensive drug therapy on serum lipid profile: a cross-sectional survey of serum lipids in male and female hypertensives. Mol Cell Biochem 2010;343:37-47. [PMID: 20521162 DOI: 10.1007/s11010-010-0496-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
24 Buongiorno AM, Morelli S, Sagratella E, Cipriani R, Mazzaferro S, Morano S, Sensi M. Immunogenicity of advanced glycation end products in diabetic patients and in nephropathic non-diabetic patients on hemodialysis or after renal transplantation. J Endocrinol Invest. 2008;31:558-562. [PMID: 18591891 DOI: 10.1007/bf03346408] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
25 Clapp C, Thebault S, Jeziorski MC, Martínez De La Escalera G. Peptide hormone regulation of angiogenesis. Physiol Rev 2009;89:1177-215. [PMID: 19789380 DOI: 10.1152/physrev.00024.2009] [Cited by in Crossref: 103] [Cited by in F6Publishing: 93] [Article Influence: 8.6] [Reference Citation Analysis]
26 Liu LL, Jiang Y, Wang LN, Yao L, Li ZL. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs 2012;72:1521-33. [PMID: 22818016 DOI: 10.2165/11635030-000000000-00000] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
27 Masuo K, Lambert GW, Esler MD, Rakugi H, Ogihara T, Schlaich MP. The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens Res 2010;33:521-8. [DOI: 10.1038/hr.2010.35] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 5.4] [Reference Citation Analysis]
28 Shutov L, Kruglikov I, Gryshchenko O, Khomula E, Viatchenko-Karpinski V, Belan P, Voitenko N. The effect of nimodipine on calcium homeostasis and pain sensitivity in diabetic rats. Cell Mol Neurobiol 2006;26:1541-57. [PMID: 16838100 DOI: 10.1007/s10571-006-9107-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
29 Rende P, Paletta L, Gallelli G, Raffaele G, Natale V, Brissa N, Costa C, Gratteri S, Giofrè C, Gallelli L. Retrospective evaluation of adverse drug reactions induced by antihypertensive treatment. J Pharmacol Pharmacother 2013;4:S47-50. [PMID: 24347982 DOI: 10.4103/0976-500X.120954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
30 Coca A. Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage. Expert Review of Cardiovascular Therapy 2014;5:147-59. [DOI: 10.1586/14779072.5.2.147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]